165,000 Shares in Immunocore Holdings plc (NASDAQ:IMCR) Acquired by Jefferies Financial Group Inc.

Jefferies Financial Group Inc. bought a new stake in shares of Immunocore Holdings plc (NASDAQ:IMCR - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 165,000 shares of the company's stock, valued at approximately $4,868,000. Jefferies Financial Group Inc. owned approximately 0.33% of Immunocore at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Immunocore by 12.9% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,393 shares of the company's stock valued at $248,000 after purchasing an additional 960 shares during the last quarter. NEOS Investment Management LLC raised its stake in Immunocore by 10.9% in the 4th quarter. NEOS Investment Management LLC now owns 11,194 shares of the company's stock worth $330,000 after acquiring an additional 1,102 shares during the last quarter. Virtus ETF Advisers LLC raised its stake in Immunocore by 39.0% in the 4th quarter. Virtus ETF Advisers LLC now owns 11,536 shares of the company's stock worth $340,000 after acquiring an additional 3,238 shares during the last quarter. XTX Topco Ltd raised its stake in Immunocore by 22.2% in the 4th quarter. XTX Topco Ltd now owns 18,896 shares of the company's stock worth $557,000 after acquiring an additional 3,437 shares during the last quarter. Finally, Barclays PLC raised its stake in Immunocore by 2,044.0% in the 4th quarter. Barclays PLC now owns 20,625 shares of the company's stock worth $608,000 after acquiring an additional 19,663 shares during the last quarter. Hedge funds and other institutional investors own 84.50% of the company's stock.

Immunocore Stock Performance

NASDAQ IMCR traded up $1.31 during trading hours on Friday, hitting $30.37. The company had a trading volume of 416,728 shares, compared to its average volume of 428,956. The company has a debt-to-equity ratio of 1.03, a quick ratio of 3.76 and a current ratio of 3.78. Immunocore Holdings plc has a 1-year low of $23.15 and a 1-year high of $55.64. The company has a market cap of $1.52 billion, a PE ratio of -31.97 and a beta of 0.75. The business has a 50 day moving average of $28.71 and a 200-day moving average of $30.06.

Immunocore (NASDAQ:IMCR - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported $0.10 EPS for the quarter, beating analysts' consensus estimates of ($0.35) by $0.45. Immunocore had a negative net margin of 15.87% and a negative return on equity of 12.84%. The business had revenue of $125.13 million during the quarter, compared to analysts' expectations of $108.82 million. During the same period in the prior year, the company earned ($0.49) earnings per share. The business's revenue was up 33.6% compared to the same quarter last year. As a group, equities research analysts expect that Immunocore Holdings plc will post -0.94 EPS for the current year.

Insider Activity

In related news, Director Bros. Advisors Lp Baker purchased 807,338 shares of the business's stock in a transaction dated Monday, March 17th. The stock was acquired at an average price of $29.72 per share, for a total transaction of $23,994,085.36. Following the acquisition, the director now directly owns 2,144,060 shares of the company's stock, valued at $63,721,463.20. This trade represents a 60.40% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 10.40% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on IMCR. HC Wainwright restated a "buy" rating and issued a $100.00 target price on shares of Immunocore in a research note on Wednesday, March 12th. Morgan Stanley reiterated an "equal weight" rating and set a $35.00 price target on shares of Immunocore in a report on Friday, March 7th. Mizuho reduced their price target on shares of Immunocore from $38.00 to $33.00 and set a "neutral" rating on the stock in a research report on Monday, April 7th. Oppenheimer increased their price objective on Immunocore from $85.00 to $86.00 and gave the stock an "outperform" rating in a research report on Thursday, May 8th. Finally, Needham & Company LLC reissued a "buy" rating and set a $71.00 target price on shares of Immunocore in a research note on Thursday, April 10th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and six have issued a buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $58.13.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.